Compare TU & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TU | MRNA |
|---|---|---|
| Founded | 1993 | 2010 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.2B | 21.6B |
| IPO Year | 2000 | 2018 |
| Metric | TU | MRNA |
|---|---|---|
| Price | $11.50 | $61.21 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 4 | 12 |
| Target Price | $17.63 | ★ $34.27 |
| AVG Volume (30 Days) | 5.5M | ★ 6.8M |
| Earning Date | 05-07-2026 | 05-01-2026 |
| Dividend Yield | ★ 9.96% | N/A |
| EPS Growth | N/A | ★ 21.77 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $19,263,000,000.00 |
| Revenue This Year | $4.94 | $9.36 |
| Revenue Next Year | $2.76 | $15.43 |
| P/E Ratio | $25.82 | ★ N/A |
| Revenue Growth | N/A | ★ 4.29 |
| 52 Week Low | $11.33 | $22.28 |
| 52 Week High | $16.74 | $67.74 |
| Indicator | TU | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 30.61 | 65.23 |
| Support Level | N/A | $45.69 |
| Resistance Level | $12.64 | N/A |
| Average True Range (ATR) | 0.23 | 4.49 |
| MACD | -0.07 | 1.59 |
| Stochastic Oscillator | 15.35 | 70.88 |
Telus is one of the Big Three wireless service providers in Canada, with over 10 million mobile phone subscribers nationwide constituting almost 30% of the total market. It is the incumbent local exchange carrier in the western Canadian provinces of British Columbia and Alberta, where it provides internet, television, and landline phone services. It also has a small wireline presence in eastern Quebec. Mostly because of recent acquisitions, more than 20% of Telus' sales now come from nontelecom businesses, most notably in the international business services, health, security, and agriculture industries. The firm has a 55% economic stake in Telus International.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.